NCT07203547View on ClinicalTrials.gov

Phase 4 Study of Laybon Tab. in Knee Osteoarthritis

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

172

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions

Osteoarthritis, KneeOsteoarthritis

Interventions

DRUG

Layla Tab.

Layla Tab., oral, twice daily, 8 weeks.

DRUG

Laybon Tab.

Laybon Tab., oral, twice daily, 8 weeks.

All Listed Sponsors

lead

Mather's Pharm. Co., Ltd.

INDUSTRY